ArticleFrontiers in immunology2025
Global research trends of tumor microenvironment in non-small cell lung cancer with epidermal growth factor receptor mutation: a bibliometric analysis from 2014 to 2023.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The evolution of real-world evidence in lung cancer: a bibliometric analysis from 2009 to 2024.Discover oncology · 2026Article
- Integration of single-cell and bulk transcriptomics to explore prognostic and immunotherapeutic characteristics of sodium overload-induced cell death in lung adenocarcinoma.Translational cancer research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, and about half of the patients had mutations in the epidermal growth factor receptor (EGFR) gene. Changes in the tumor microenvironment after EGFR mutation are closely related to tumor progression and treatment efficacy. Materials and methods: We searched the Web of Science Core Collection database to select the articles related to tumor microenvironment in non-small cell lung cancer with epidermal growth factor receptor mutation. The countries/regions, institutes, authors, journals, references, and keywords were visualized and analyzed. Results: 227 relevant studies were obtained from WoSCC. These articles came from 102 countries and 1179 institutions. After network analysis, it was found that the intensity of USA cooperation with China was the greatest (LS=13), followed by cooperation with South Korea (LS=3) and with Japan (LS=3). A total of 2267 authors participated the all 227 articles. 112 journals were covered, and Conclusion: Effective drug treatment of advanced NSCLC with EGFR mutations after failure of first-line chemotherapy is one of the hotspots, in which the efficacy of immune checkpoint inhibitors may be the direction of the current and future studies that need to find a breakthrough.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.